[1]孙耀华,汪润秋,赵 静,等.结直肠癌组织中KRAS、NRAS及BRAF基因突变状态与临床病理特征的关系[J].郑州大学学报(医学版),2021,(01):53-57.
 SUN Yaohua,WANG Runqiu,ZHAO Jing,et al.KRAS, NRAS and BRAF gene mutation status in colorectal cancer and its correlation with clinicopathological features[J].JOURNAL OF ZHENGZHOU UNIVERSITY(MEDICAL SCIENCES),2021,(01):53-57.
点击复制

结直肠癌组织中KRAS、NRAS及BRAF基因突变状态与临床病理特征的关系()
分享到:

《郑州大学学报(医学版)》[ISSN:1671-6825/CN:41-1340/R]

卷:
期数:
2021年01期
页码:
53-57
栏目:
应用研究
出版日期:
2021-01-20

文章信息/Info

Title:
KRAS, NRAS and BRAF gene mutation status in colorectal cancer and its correlation with clinicopathological features
作者:
孙耀华汪润秋赵 静李雪莹杨慧玲白辰光
海军军医大学第一附属医院病理科 上海 200433
Author(s):
SUN YaohuaWANG RunqiuZHAO JingLI XueyingYANG HuilingBAI Chenguang
Department of Pathology,the First Affiliated Hospital,Naval Military Medical University,Shanghai 200433
关键词:
结直肠癌 KRAS NRAS BRAF 临床病理特征
Keywords:
colorectal cancer KRAS NRAS BRAF clinicopathological feature
分类号:
R735.3
摘要:
目的:探讨结直肠癌组织中KRAS、NRAS及BRAF基因突变状态与临床病理特征的关系。方法:选取接受根治手术治疗的1 205例结直肠癌患者的肿瘤组织标本,采用突变扩增阻滞系统检测KRAS、NRAS、BRAF基因的突变状态。1 205例患者中,<40岁88例,40~岁663例,≥60岁454例; 男722例,女483例; 原发于右半结肠244例,左半结肠300例,直肠661例; 普通型腺癌1 029例,黏液腺癌176例; 低分化132例,高/中分化1 073例; 肿瘤最大径<4 cm者498例,≥4 cm者707例; 区域淋巴结转移510例; pTNM分期Ⅰ期212例,Ⅱ期439例,Ⅲ/Ⅳ期554例。结果:1 205例结直肠癌组织中共检出KRAS基因突变538例(44.6%), NRAS基因突变33例(2.7%),BRAF基因突变38例(3.2%),不存在交叉突变。KRAS基因突变在黏液腺癌、高/中分化癌组织中的检出率高于普通型腺癌、低分化癌(P<0.05)。不同临床病理特征结直肠癌组织中NRAS基因突变检出率差异无统计学意义(P>0.05),在<40岁的患者中未检出。原发于右半结肠、黏液腺癌、低分化、肿瘤最大径≥4 cm、有淋巴结转移、pTNM分期Ⅲ/Ⅳ期的癌组织中BRAF基因突变检出率更高(P<0.05)。结论:KRAS基因突变与结直肠癌组织学类型和肿瘤分化程度关系密切,BRAF基因突变与多种不良预后相关临床病理特征关系密切。
Abstract:
Aim:To investigate the relationship between KRAS, NRAS and BRAF gene mutations and clinicopathological features in colorectal cancer tissue.Methods:A total of 1 205 colorectal cancer patients were enrolled in this study.The mutation status of KRAS, NRAS and BRAF genes was detected using amplification refractory mutation system.Among the 1 205 patients, 88 patients were <40 years, 663 patients were 40- years old, and 454 patients were ≥60 years old; 722 males and 483 females; primary site were right hemicolon in 244 cases, left hemicolon in 300 cases and rectum in 661 cases; 1 029 cases were common adenocarcinoma and 176 cases were mucinous adenocarcinoma; 132 cases with poor differentiation and 1 073 cases with well/moderately differentiation; maximum tumor diameter of 498 patients were <4 cm and that of 707 patients were ≥4 cm; 510 cases with regional lymph node metastasis; pTNM stage Ⅰ in 212 cases, stage Ⅱ in 439 cases, and stage Ⅲ/Ⅳ in 554 cases.Results:The mutation detection rate of KRAS,NRAS,BRAF gene were 44.6%(538/1 205),2.7%(33/1 205)and 3.2%(38/1 205),respectively.There was no crossover mutation.The mutation detection rate of KRAS gene in mucinous adenocarcinoma was higher than that in non-special type adenocarcinoma(P<0.05), in well/moderately differentiated adenocarcinoma was higher than that in poorly differentiated carcinoma(P<0.05).There was no significant differences in NRAS gene mutation status among the colorectal cancer tissue with different clinicopathological features(P>0.05).The mutation detection rate of BRAF gene was higher in the colorectal cancer tissue with primary site of right colon, mucinous adenocarcinoma, poor differentiation, the largest size of tumor ≥4 cm, lymph node metastasis or pTNM stage Ⅲ/Ⅳ(P<0.05).Conclusion:KRAS gene mutation is associated with histological type and tumor differentiation.BRAF gene mutation is associated with a variety of clinicopathological features indicating poor prognosis.

参考文献/References:

[1] SIEGEL RL,MILLER KD,GODING SAUER A,et al.Colorectal cancer statistics,2020 [J].CA Cancer J Clin,2020,70(3):145
[2] CHEN WQ,XIA CF,ZHENG RS,et al.Disparities by province,age,and sex in-specific cancer burden attributable to 23 potentially modifiable risk factors in China: acomparative risk assessment[J].Lancet Glob Health,2019,7(2):e257
[3] FENG RM,ZONG YN,CAO SM,et al.Current cancer situation in China: good or bad news from the 2018 Global Cancer Statistics? [J].Cancer Commun(Lond),2019,39(1):22
[4] 《结直肠癌分子生物标志物检测专家共识》编写组.结直肠癌分子生物标志物检测专家共识[J].中华病理学杂志,2018,47(4):237
[5] CHAN E.Angiogenesis in colorectal cancer:antibodies[J].Cancer J,2016,22(3):179
[6] 张凯,顾腾振.结直肠癌组织K-ras,BRAF及PIK3CA基因突变的检测及其与临床病理特征的关系[J].广西医科大学学报,2016,33(2):299
[7] 吴文辉,肖隆斌,汤友珍,等.K-ras基因突变与结直肠癌生物学行为的关系[J].中国病理生理杂志,2009,25(11):2159
WU WH,XIAO LB,TANG YZ,et al.Relationship between mutated k-ras and biological behavior of colorectal cancer[J].Chinese Journal of Pathophysiology,2009,25(11):2159
[8] RUI Y,WANG C,ZHOU Z,et a1.K-Ras mutation and prognosis of colorectal cancer:a meta-analysis[J].Hepatogastroenterology,2015,62(137):19
[9] 刘珊,王丹,卢福昱,等.结直肠癌组织中K-ras基因突变情况及其临床意义[J].山东医药,2015,55(36):1
LIU S,WANG D,LU FY,et al.Mutation of K-ras gene in colorectal cancer tissue and its clinical significance[J].Shandong Medicine Journal,2015,55(36):1
[10]DE ROOCK W,CLAES B,BERNASCONI D,et al.Effect of KRAS,BRAF,NRAS,and PIK3CA mutations on the efficacy of cetuximab plus chemotherapy in chemotherapy refractory metastatic colorectal cancer:a retrospective consortium analysis[J].Lancet Oncol,2010,11(8): 753
[11]GAO J,WANG TT,YU JW,et al.Wild-type KRAS and BRAF could predict response to cetuximab in Chinese colorectal cancer patients[J].Chin J Cancer Res,2011,23(4):271
[12]高静,孙志伟,李艳艳,等.中国结直肠癌患者966例中KRAS和BRAF基因突变分析[J].中华病理学杂志,2012,41(9):579
GAO J,SUN ZW,LI YY,et al.Mutations of KRAS and BRAF in Chinese patients with colorectal carcinoma: analyses of 966 cases[J].Chinese Journal of Pathology,2012,41(9):579
[13]MARTINETTI D,COSTANZO R,KADARE S,et a1.KRAS and BRAF mutational status in colon cancer from Albanian patients[J].Diagn Pathal,2014,9:187
[14]CHEN D,HUANG JF,LIU K,et al.BRAF V600E mutation and its association with clinicopathological features of colorectal cancer: a systematic review and meta-analysis [J].PLoS One,2014,9(3):e90607
[15]AHN TS,JEONG D,SON MW,et al.The BRAF mutation is associated with the prognosis in colorectal cancer[J].J Cancer Res Clin Oncol,2014,140(11):1863

相似文献/References:

[1]冯静)△,陈小兵),赵明耀),等.合并肝转移的结直肠癌组织中VEGF和Survivin蛋白的表达*[J].郑州大学学报(医学版),2010,(02):207.
 FENG Jing),CHEN Xiaobing),ZHAO Mingyao),et al.Expression of VEGF and Survivin protein in colorectal carcinoma tissue with liver metastasis[J].JOURNAL OF ZHENGZHOU UNIVERSITY(MEDICAL SCIENCES),2010,(01):207.
[2]刘天舟△,王瑞.结直肠癌患者血清中IGF1、MMP7和IGFBP3水平分析[J].郑州大学学报(医学版),2011,(05):726.
 LIU Tianzhou,WANG Rui.Levels of serum IGFI,MMP7 and IGFBP3 in colorectal cancer patients[J].JOURNAL OF ZHENGZHOU UNIVERSITY(MEDICAL SCIENCES),2011,(01):726.
[3]袁娜娜,卢高峰,唐芙爱#.人结直肠癌组织中肿瘤相关巨噬细胞的检测[J].郑州大学学报(医学版),2013,(01):106.
 YUAN Nana,LU Gaofeng,TANG Fuai.Detection of tumorassociated macrophages in colorectal cancer tissue[J].JOURNAL OF ZHENGZHOU UNIVERSITY(MEDICAL SCIENCES),2013,(01):106.
[4]季润元)△,史恩溢),王永实),等.结直肠癌组织中运动相关蛋白1/CD9和ME491/CD63的表达*[J].郑州大学学报(医学版),2012,(06):782.
 JI Runyuan,SHI Enyi,WANG Yongshi,et al.Expressions of MRP1/CD9 and ME491/CD63 in colorectal carcinoma tissue[J].JOURNAL OF ZHENGZHOU UNIVERSITY(MEDICAL SCIENCES),2012,(01):782.
[5]王朝杰,马宁,周云#.结直肠癌组织和结肠癌细胞中miR31的表达及功能*[J].郑州大学学报(医学版),2013,(05):625.
 WANG Chaojie,MA Ning,ZHOU Yun.Expression and function of miR31 in colorectal cancer tissue and HCT116 cells[J].JOURNAL OF ZHENGZHOU UNIVERSITY(MEDICAL SCIENCES),2013,(01):625.
[6]王瑞华),谢建国)#,付强),等.结直肠癌组织中Ang2、Tie2 mRNA的表达及Kras基因突变的检测*[J].郑州大学学报(医学版),2013,(05):629.
 WANG Ruihua),XIE Jianguo),FU Qiang),et al.Expression of Ang2,Tie2 mRNA and Kras gene mutation in human colorectal cancer tissue[J].JOURNAL OF ZHENGZHOU UNIVERSITY(MEDICAL SCIENCES),2013,(01):629.
[7]杨晓利),王峰),夏金),等.替吉奥或卡培他滨联合奥沙利铂一线治疗晚期结直肠癌效果对比分析[J].郑州大学学报(医学版),2013,(05):687.
 YANG Xiaoli),WANG Feng),XIA Jin),et al.Retrospective study on S1 plus oxaliplatin versus capecitabine plus oxaliplatin for firstline treatment of patients with advanced colorectal cancer[J].JOURNAL OF ZHENGZHOU UNIVERSITY(MEDICAL SCIENCES),2013,(01):687.
[8]吴新新,马杰,任鹏飞,等.结直肠癌KRAS、NRAS和BRAF 基因突变与病理特征、吸烟和饮酒之间的相关性[J].郑州大学学报(医学版),2016,(01):39.
 WU Xinxin,MA Jie,REN Pengfei,et al.Relationship between KRAS,NRAS and BRAF gene mutation and pathological features,smoking and drinking of patients with colorectal cancer[J].JOURNAL OF ZHENGZHOU UNIVERSITY(MEDICAL SCIENCES),2016,(01):39.
[9]付 强,张金岱,谢建国.上调睾丸特异性Y样蛋白5的表达对LoVo细胞侵袭、迁移及STAT3蛋白表达的影响[J].郑州大学学报(医学版),2019,(06):845.[doi:10.13705/j.issn.1671-6825.2018.08.012]
 FU Qiang,ZHANG Jindai,XIE Jianguo.Effects of up-regulating TSPYL5 on invasion and metastasis of LoVo cells and STAT3 protein[J].JOURNAL OF ZHENGZHOU UNIVERSITY(MEDICAL SCIENCES),2019,(01):845.[doi:10.13705/j.issn.1671-6825.2018.08.012]
[10]郑孝振,任益锋,刘 静,等.七氟醚对结直肠癌SW480细胞增殖、凋亡的影响[J].郑州大学学报(医学版),2020,(05):640.[doi:10.13705/j.issn.1671-6825.2019.09.081]
 ZHENG Xiaozhen,REN Yifeng,LIU Jing,et al.Effect of sevoflurane on proliferation and apoptosis of colorectal cancer SW480 cells[J].JOURNAL OF ZHENGZHOU UNIVERSITY(MEDICAL SCIENCES),2020,(01):640.[doi:10.13705/j.issn.1671-6825.2019.09.081]

备注/Memo

备注/Memo:
【基金项目】上海卫生计生系统重要薄弱学科建设计划项目(2015ZB0202); 海军军医大学第一附属医院“234”攀峰计划-平台学科夯基项目(2019YPT003)
【作者简介】白辰光,通信作者,男,1976年12月生,博士,副教授,副主任医师,研究方向:胃肠道肿瘤病理,E-mail:bcg709@126.com; 汪润秋,通信作者,男,1994年8月生,学士,技师,研究方向:分子病理技术,E-mail:155011827@qq.com
更新日期/Last Update: 2021-02-15